Mesenteric Venous Thrombosis
Acosta, Stefan LU
and Björck, Martin
(2022)
1-2.
p.2-1808
- Abstract
Acute mesenteric venous thrombosis accounts for up to 20% of all patients with acute mesenteric ischemia in high-income countries and is a very difficult disease to diagnose on clinical grounds. However, owing to the increased availability and evolution of computed tomography in high-income countries, early diagnosis prior to the development of peritonitis is often possible. First-line therapy is full-dose anticoagulation intravenously, whereas endovascular therapy including thrombolysis may be considered in cases refractory to anticoagulation therapy. Exploratory laparotomy and bowel resection are performed in patients developing peritonitis or not responding to anticoagulation. When the patient’s intestinal function has recovered,... (More)
Acute mesenteric venous thrombosis accounts for up to 20% of all patients with acute mesenteric ischemia in high-income countries and is a very difficult disease to diagnose on clinical grounds. However, owing to the increased availability and evolution of computed tomography in high-income countries, early diagnosis prior to the development of peritonitis is often possible. First-line therapy is full-dose anticoagulation intravenously, whereas endovascular therapy including thrombolysis may be considered in cases refractory to anticoagulation therapy. Exploratory laparotomy and bowel resection are performed in patients developing peritonitis or not responding to anticoagulation. When the patient’s intestinal function has recovered, switch to oral anticoagulation can be performed. Direct oral anticoagulants have emerged as a better alternative to vitamin K antagonists. Patients with no strong permanent trigger factor for mesenteric venous thrombosis should undergo screening for inherited disorders such as factor V Leiden mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, and antithrombin III deficiency as well as acquired disorders such as JAK2 V617F mutation, lupus anticoagulant, and cardiolipin antibodies.
(Less)
- author
- Acosta, Stefan
LU
and Björck, Martin
- organization
- publishing date
- 2022-01-01
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- acute mesenteric ischemia, anticoagulation, factor V Leiden mutation, mesenteric venous thrombosis, risk factors, thrombophilia
- host publication
- Rutherford's Vascular Surgery and Endovascular Therapy, Tenth Edition : Volume 1-2 - Volume 1-2
- volume
- 1-2
- edition
- 10
- pages
- 2 - 1808
- publisher
- Elsevier
- external identifiers
-
- scopus:85216427080
- ISBN
- 9780323775571
- 9780323775601
- DOI
- 10.1016/B978-0-323-77557-1.00137-5
- language
- English
- LU publication?
- yes
- id
- c41326c1-10b4-4b7e-9e57-2a521d9a7733
- date added to LUP
- 2025-06-03 08:30:38
- date last changed
- 2025-06-04 02:47:07
@inbook{c41326c1-10b4-4b7e-9e57-2a521d9a7733,
abstract = {{<p>Acute mesenteric venous thrombosis accounts for up to 20% of all patients with acute mesenteric ischemia in high-income countries and is a very difficult disease to diagnose on clinical grounds. However, owing to the increased availability and evolution of computed tomography in high-income countries, early diagnosis prior to the development of peritonitis is often possible. First-line therapy is full-dose anticoagulation intravenously, whereas endovascular therapy including thrombolysis may be considered in cases refractory to anticoagulation therapy. Exploratory laparotomy and bowel resection are performed in patients developing peritonitis or not responding to anticoagulation. When the patient’s intestinal function has recovered, switch to oral anticoagulation can be performed. Direct oral anticoagulants have emerged as a better alternative to vitamin K antagonists. Patients with no strong permanent trigger factor for mesenteric venous thrombosis should undergo screening for inherited disorders such as factor V Leiden mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, and antithrombin III deficiency as well as acquired disorders such as JAK2 V617F mutation, lupus anticoagulant, and cardiolipin antibodies.</p>}},
author = {{Acosta, Stefan and Björck, Martin}},
booktitle = {{Rutherford's Vascular Surgery and Endovascular Therapy, Tenth Edition : Volume 1-2}},
isbn = {{9780323775571}},
keywords = {{acute mesenteric ischemia; anticoagulation; factor V Leiden mutation; mesenteric venous thrombosis; risk factors; thrombophilia}},
language = {{eng}},
month = {{01}},
pages = {{2--1808}},
publisher = {{Elsevier}},
title = {{Mesenteric Venous Thrombosis}},
url = {{http://dx.doi.org/10.1016/B978-0-323-77557-1.00137-5}},
doi = {{10.1016/B978-0-323-77557-1.00137-5}},
volume = {{1-2}},
year = {{2022}},
}